London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Hikma’s CEO, said: “I am pleased ...

Hikma Pharmaceuticals (GB:HIK) has released an update. Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.99% to £19.98 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0. ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hikma Pharmaceuticals Usa Inc was founded in 2011 and operates in Eatontown, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100 ...

Hikma started CohenCare in 2020 with 3 partners after recognizing a significant gap in compassionate home care options in her community. Her desire to create a nurturing environment for those in ...

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.